Substituted pteridines useful for the treatment and prevention of viral infections

1. A pteridine derivative selected from the group consisting of:

4-ethoxy-6-(4-(trifluoromethoxy)phenyl)pteridin-2-amine,

dimethyl (4-(2-amino-4-ethoxypteridin-yl)phenyl)methylphosphonate,

4-ethoxy-6-(pyridin-3-yl)pteridin-2-amine,

4-ethoxy-6-(1H-pyrazol-5-yl)pteridin-2-amine,

4-ethoxy-6-(pyrimidin-5-yl)pteridin-2-amine,

4-ethoxy-6-(2-fluoropyridin-3-yl)pteridin-2-amine,

4-ethoxy-6-(1H-indol-5-yl)pteridin-2-amine,

4-ethoxy-6-(4-(methylsulfonyl)phenyl)pteridin-2-amine,

4-ethoxy-6-(pyridin-4-yl)pteridin-2-amine,

4-ethoxy-6-(1H-pyrazol-4-yl)pteridin-2-amine,

4-ethoxy-6-(3-(trifluoromethoxy)phenyl)pteridin-2-amine,

4-(2-amino-4-ethoxypteridin-6-yl)-N-cyclopropylbenzamide,

5-(2-amino-4-ethoxypteridin-6-yl)thiophene-2-carbonitrile,

4-ethoxy-6-(2-(trifluoromethoxy)phenyl)pteridin-2-amine,

6-(5-chlorothiophen-2-yl)-4-ethoxypteridin-2-amine,

1-(4-(2-amino-4-ethoxypteridin-6-yl)phenyl)pyrrolidin-2-one,

5-(2-amino-4-ethoxypteridin-6-yl)indolin-2-one,

4-ethoxy-6-(6-methoxypyridin-3-yl)pteridin-2-amine,

4-ethoxy-6-(isoxazol-4-yl)pteridin-2-amine,

methyl 4-(2-amino-4-ethoxypteridin-6-yl)phenylcarbamate,

6-(benzofuran-2-yl)-4-ethoxypteridin-2-amine,

4-ethoxy-6-morpholinopteridin-2-amine,

4-ethoxy-6-(3-methylpyridin-4-yl)pteridin-2-amine,

4-ethoxy-6-(2-methoxypyridin-4-yl)pteridin-2-amine,

4-ethoxy-6-(2-methylpyridin-4-yl)pteridin-2-amine,

4-ethoxy-6-(pyridin-2-yl)pteridin-2-amine,

4-morpholino-6-(3-(trifluoromethoxy)phenyl)pteridin-2-amine,

4-morpholino-6-(4-(trifluoromethoxy)phenyl)pteridin-2-amine,

4-morpholino-6-(4-(morpholinomethyl)phenyl)pteridin-2-amine,

dimethyl (4-(2-amino-4-morpholinopteridin-6-yl)phenyl)methylphosphonate,

6-(4-(methylsulfonyl)phenyl)-4-morpholinopteridin-2-amine,

6-(1H-indol-5-yl)-4-morpholinopteridin-2-amine,

4-morpholino-6-(pyrimidin-5-yl)pteridin-2-amine,

4-morpholino-6-(pyridin-3-yl)pteridin-2-amine,

6-(2-fluoropyridin-3-yl)-4-morpholinopteridin-2-amine,

6-(furan-3-yl)-4-morpholinopteridin-2-amine,

4-morpholino-6-(1H-pyrazol-5-yl)pteridin-2-amine,

4-(2-amino-4-morpholinopteridin-6-yl)-N-cyclopropylbenzamide,

4-morpholino-6-(pyridin-4-yl)pteridin-2-amine,

4-morpholino-6-(1H-pyrazol-4-yl)pteridin-2-amine,

5-(2-amino-4-morpholinopteridin-6-yl)thiophene-2-carbonitrile,

6-(benzo[b]thiophen-2-yl)-4-morpholinopteridin-2-amine,

6-(5-chlorothiophen-2-yl)-morpholinopteridin-2-amine,

1-(4-(2-amino-4-morpholinopteridin-6-yl)phenyl)pyrrolidin-2-one,

methyl 4-(2-amino-4-morpholinopteridin-6-yl)phenylcarbamate,

6-(6-methoxypyridin-3-yl)-4-morpholinopteridin-2-amine,

6-(isoxazol-4-yl)-4-morpholinopteridin-2-amine,

6-(benzofuran-2-yl)-4-morpholinopteridin-2-amine,

5-(2-amino-4-morpholinopteridin-6-yl)indolin-2-one,

N-(4-(2-amino-4-morpholinopteridin-6-yl)phenyl)isobutyramide,

N-(4-(2-amino-4-morpholinopteridin-6-yl)phenyl)pivalamide,

(S)-tert-butyl 1-(4-(2-amino-4-morpholinopteridin-6-yl)phenylamino)-3-hydroxy-1-oxopropan-2-ylcarbamate,

(S)-tert-butyl 1-(4-(2-amino-4-morpholinopteridin-6-yl)phenylamino)-1-oxopropan-2-ylcarbamate,

cyclopropane carboxylic acid [4-(2-amino-4-morpholin-4-yl-pteridin-6-yl)-phenyl]-amide,

6-(2,3-difluorophenyl)-pteridine-2,4-diamine,

(S)-2-amino-N-(4-(2-amino-4-morpholinopteridin-6-yl)phenyl)-3-hydroxypropanamide,

(S)-2-amino-N-(4-(2-amino-4-morpholinopteridin-6-yl)phenyl)propanamide,

4-[2-Amino-6-(4-fluoro-phenyl)-pteridin-4-yloxy]-2-methyl-butan-2-ol,

6-(4-Fluoro-phenyl)-4-(2-morpholin-4-yl-ethoxy)-pteridin-2-ylamine,

6-(4-Fluoro-phenyl)-4-(3-morpholin-4-yl-propoxy)-pteridin-2-ylamine,

4-Cyclopropylmethoxy-6-(4-fluoro-phenyl)-pteridin-2-ylamine,

4-Cyclobutylmethoxy-6-(4-fluoro-phenyl)-pteridin-2-ylamine,

6-(4-Fluoro-phenyl)-4-(tetrahydro-furan-3-yloxy)-pteridin-2-ylamine,

4-Ethylsulfanyl-6-(4-fluoro-phenyl)-pteridin-2-ylamine,

6-(4-fluoro-phenyl)-pteridine-2,4-diamine,

N-4-Cyclopropyl-6-(4-fluoro-phenyl)-pteridine-2,4-diamine,

4-(2,6-Dimethyl-morpholin-4-yl)-6-(4-fluoro-phenyl)-pteridin-2-ylamine,

N-4-Cyclohexyl-6-(4-fluoro-phenyl)-pteridine-2,4-diamine,

N-4-(3-Methyl-benzyl)-6-(4-fluoro-phenyl)-pteridine-2,4-diamine,

N-4-(3-Fluoro-benzyl)-6-(4-fluoro-phenyl)-pteridine-2,4-diamine,

6-(4-Fluoro-phenyl)-4-(4-methyl-piperazin-1-yl)-pteridin-2-ylamine,

6-(4-Fluoro-phenyl)-4-piperazin-1-yl-pteridin-2-ylamine,

N-4-Cyclopropylmethyl-6-(4-fluoro-phenyl)-pteridine-2,4-diamine,

6-(4-Fluoro-phenyl)-4-pyrrolidin-1-yl-pteridin-2-ylamine,

4-Ethoxy-6-(4-fluoro-phenyl)-pteridine,

4-isopropoxy-6-(4-fluoro-phenyl)-pteridine,

4-(2-methoxy-ethoxy)-6-(4-fluoro-phenyl)-pteridine,

[6-(4-Fluoro-phenyl)-pteridin-4-yl]-(4-methyl-cyclohexyl)-amine,

[6-(4-Fluoro-phenyl)-pteridin-4-yl]-(4-methyl-cyclohexyl)-amine, and

4-Ethylsulfanyl-6-(4-fluoro-phenyl)-pteridine

and/or a pharmaceutically acceptable addition salt thereof and/or a stereoisomer thereof and/or a mono- or a di-N-oxide thereof.

2. A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 1 , or a pharmaceutically acceptable addition salt thereof, and one or more pharmaceutically acceptable excipients.

3. A pharmaceutical composition according to claim 2 , further comprising one or more other antiviral drugs.

4. A method of treatment of an infection due to a virus, by administering to a patient in need thereof a therapeutically effective amount of a pteridine derivative according to claim 1 , or a pharmaceutically acceptable addition salt thereof, wherein said virus belongs to the Flaviviridae family.

5. A method according to claim 4 , wherein said virus belongs to a genus selected from the group consisting of Genus Flavivirus , Genus Hepacivirus and Genus Pestivirus.

6. A method according to claim 4 , wherein said virus is hepatitis C virus.

7. A method according to claim 4 , wherein said administration is oral administration.

8. A method according to claim 4 , wherein said therapeutically effective amount is from 0.01 mg to 20 mg per day per kg bodyweight of said patient.

9. A method according to claim 4 , wherein said at least one pteridine derivative is administered together with one or more other antiviral drugs.

10. A method according to claim 9 , wherein said other antiviral drug is selected from the group consisting of interferon alpha, ribavirin, NS3 protease inhibitors, and nucleoside- or non-nucleoside-based inhibitors of NS5B polymerase.

11. A pteridine derivative selected from the group consisting of:

4-(2-amino-4-ethoxypteridin-6-yl)-N-methylbenzamide,

6-(benzo[b]thiophen-2-yl)-4-ethoxypteridin-2-amine,

6-(4-Fluoro-phenyl)-4-(2,2,2-trifluoro-ethoxy)-pteridin-2-ylamine,

4-Benzyloxy-6-(4-fluoro-phenyl)-pteridin-2-ylamine,

and/or a pharmaceutically acceptable addition salt thereof and/or a stereoisomer thereof and/or a mono- or a di-N-oxide thereof.

12. A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 11 , or a pharmaceutically acceptable addition salt thereof, and one or more pharmaceutically acceptable excipients.

13. A pharmaceutical composition according to claim 12 , further comprising one or more other antiviral drugs.